Cargando…

Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study

OBJECTIVE: To evaluate the efficacy and safety of intravenous immunoglobulin G (IVIG) in infants with ABO hemolytic disease of the newborn (HDN). METHODS: Infants with moderate-to-severe ABO HDN during early neonatal period (<7 days) at our hospital in 2017 were included in this retrospective stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Jiarong, Zhan, Canyang, Yuan, Tianming, Chen, Xiangxiang, Ni, Yanyan, Shen, Ying, Chen, Weiwei, Wu, Tai, Yu, Huimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225508/
https://www.ncbi.nlm.nih.gov/pubmed/33589732
http://dx.doi.org/10.1038/s41372-021-00963-5
_version_ 1783712106435051520
author Pan, Jiarong
Zhan, Canyang
Yuan, Tianming
Chen, Xiangxiang
Ni, Yanyan
Shen, Ying
Chen, Weiwei
Wu, Tai
Yu, Huimin
author_facet Pan, Jiarong
Zhan, Canyang
Yuan, Tianming
Chen, Xiangxiang
Ni, Yanyan
Shen, Ying
Chen, Weiwei
Wu, Tai
Yu, Huimin
author_sort Pan, Jiarong
collection PubMed
description OBJECTIVE: To evaluate the efficacy and safety of intravenous immunoglobulin G (IVIG) in infants with ABO hemolytic disease of the newborn (HDN). METHODS: Infants with moderate-to-severe ABO HDN during early neonatal period (<7 days) at our hospital in 2017 were included in this retrospective study. Patients treated with IVIG and phototherapy were classified as the IVIG group, and those who only received phototherapy were classified as the phototherapy only group. RESULTS: Forty-six patients were classified into the IVIG group and 68 other patients were classified into the phototherapy only group. There was no significant difference in duration of phototherapy, hospitalization periods, needs for exchange transfusion, transfusions, and incidence of bilirubin-induced neurological sequelae between these two groups (P = 0.20, 0.27, 0.65, 0.47, 0.78, respectively). CONCLUSION: It seems unnecessary to expose neonates to IVIG in moderate-to-severe ABO HDN when the available data show no appreciable benefits.
format Online
Article
Text
id pubmed-8225508
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group US
record_format MEDLINE/PubMed
spelling pubmed-82255082021-07-13 Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study Pan, Jiarong Zhan, Canyang Yuan, Tianming Chen, Xiangxiang Ni, Yanyan Shen, Ying Chen, Weiwei Wu, Tai Yu, Huimin J Perinatol Article OBJECTIVE: To evaluate the efficacy and safety of intravenous immunoglobulin G (IVIG) in infants with ABO hemolytic disease of the newborn (HDN). METHODS: Infants with moderate-to-severe ABO HDN during early neonatal period (<7 days) at our hospital in 2017 were included in this retrospective study. Patients treated with IVIG and phototherapy were classified as the IVIG group, and those who only received phototherapy were classified as the phototherapy only group. RESULTS: Forty-six patients were classified into the IVIG group and 68 other patients were classified into the phototherapy only group. There was no significant difference in duration of phototherapy, hospitalization periods, needs for exchange transfusion, transfusions, and incidence of bilirubin-induced neurological sequelae between these two groups (P = 0.20, 0.27, 0.65, 0.47, 0.78, respectively). CONCLUSION: It seems unnecessary to expose neonates to IVIG in moderate-to-severe ABO HDN when the available data show no appreciable benefits. Nature Publishing Group US 2021-02-15 2021 /pmc/articles/PMC8225508/ /pubmed/33589732 http://dx.doi.org/10.1038/s41372-021-00963-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Pan, Jiarong
Zhan, Canyang
Yuan, Tianming
Chen, Xiangxiang
Ni, Yanyan
Shen, Ying
Chen, Weiwei
Wu, Tai
Yu, Huimin
Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study
title Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study
title_full Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study
title_fullStr Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study
title_full_unstemmed Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study
title_short Intravenous immunoglobulin G in the treatment of ABO hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study
title_sort intravenous immunoglobulin g in the treatment of abo hemolytic disease of the newborn during the early neonatal period at a tertiary academic hospital: a retrospective study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225508/
https://www.ncbi.nlm.nih.gov/pubmed/33589732
http://dx.doi.org/10.1038/s41372-021-00963-5
work_keys_str_mv AT panjiarong intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy
AT zhancanyang intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy
AT yuantianming intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy
AT chenxiangxiang intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy
AT niyanyan intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy
AT shenying intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy
AT chenweiwei intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy
AT wutai intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy
AT yuhuimin intravenousimmunoglobulinginthetreatmentofabohemolyticdiseaseofthenewbornduringtheearlyneonatalperiodatatertiaryacademichospitalaretrospectivestudy